Erratum: Expression of concern: Tobacco-specific carcinogens induce hypermethylation, DNA adducts, and DNA damage in bladder cancer (Cancer Prevention Research (2017) 10 (588-597) DOI: 10.1158/1940-6207.CAPR-17-0198);Tobacco-specific carcinogens induce hypermethylation, DNA adducts, and DNA damage in bladder cancer

Cancer Prevention Research

Volumn 10, Issue 10, 2017, Pages 588-597

  Jin, Feng ^a   Thaiparambil, Jose ^b   Donepudi, Sri Ramya ^a   Vantaku, Venkatrao ^a   Piyarathna, Danthasinghe Waduge Badrajee ^a   Maity, Suman ^a   Krishnapuram, Rashmi ^a   Putluri, Vasanta ^a   Gu, Franklin ^a   Purwaha, Preeti ^a   Bhowmik, Salil Kumar ^a   Ambati, Chandrashekar R ^a   Von Rundstedt, Friedrich Carl ^a,c   Roghmann, Florian ^d   Berg, Sebastian ^d   Noldus, Joachim ^d   Rajapakshe, Kimal ^a   Godde, Daniel ^e   Roth, Stephan ^e   Storkel, Stephan ^e   Degener, Stephan ^e   Michailidis, George ^f   Kaipparettu, Benny Abraham ^a   Karanam, Balasubramanyam ^g   Terris, Martha K ^h   Kavuri, Shyam M ^a   Lerner, Seth P ^a   Kheradmand, Farrah ^a   Coarfa, Cristian ^a   Sreekumar, Arun ^a   Lotan, Yair ⁱ   El Zein, Randa ^b   Putluri, Nagireddy ^a   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

^f UNIVERSITY OF FLORIDA   (United States)

^g TUSKEGEE UNIVERSITY   (United States)

^h AUGUSTA UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; BENZO[A]PYRENE; DECITABINE; DNA METHYLTRANSFERASE 1; METHIONINE; POLYCYCLIC AROMATIC HYDROCARBON; 4-(N-METHYL-N-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; ALKANONE; AZACITIDINE; CARCINOGEN; DNA (CYTOSINE 5) METHYLTRANSFERASE 1; DNMT1 PROTEIN, HUMAN; METHYLETHYL KETONE; MUTAGENIC AGENT; NITROSAMINE; TUMOR MARKER;

ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; COHORT ANALYSIS; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DNA METHYLATION; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; METABOLITE; METABOLOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; TOBACCO; ANALOGS AND DERIVATIVES; BLADDER TUMOR; BLOOD; CANCER GRADING; CHEMISTRY; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; FEMALE; MALE; METABOLISM; METABOLOMICS; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; TOXICITY; TUMOR CELL LINE; URINE; VALIDATION STUDY;

AZACITIDINE; BENZO(A)PYRENE; BIOMARKERS, TUMOR; BUTANONES; CARCINOGENS; CELL LINE, TUMOR; COHORT STUDIES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DNA ADDUCTS; DNA DAMAGE; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; METABOLOME; METABOLOMICS; MUTAGENS; NEOPLASM GRADING; NITROSAMINES; POLYCYCLIC AROMATIC HYDROCARBONS; RISK ASSESSMENT; SMOKING; TOBACCO; TOBACCO PRODUCTS; URINARY BLADDER NEOPLASMS;

EID: 85030689074     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-19-0406     Document Type: Erratum

References (50)

1. Smart CR. Bladder cancer survival statistics. J Occup Med 1990;32:926–8.
2. Rink M, Soave A, Chun FK, Dahlem R, Minner S, Kluth LA, et al. Influence of preoperatively detected circulating tumor cells on the outcome of patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Clin Oncol 2012;30:268.
3. Nuhn P, Novara G, Seitz C, Gupta A, Matsumoto K, Kassouf W, et al. Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study. World J Urol 2015; 33:1005–13.
4. Scosyrev E, Golijanin D, Wu G, Messing E. The burden of bladder cancer in men and women: analysis of the years of life lost. BJU Int 2012;109:57–62.
5. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000;86:289–94.
6. Gupta RC, Arif JM, Gairola CG. Enhancement of pre-existing DNA adducts in rodents exposed to cigarette smoke. Mutat Res 1999;424:195–205.
7. Auerbach O, Garfinkel L. Histologic changes in the urinary bladder in relation to cigarette smoking and use of artificial sweeteners. Cancer 1989;64:983–7.
8. Cancer.org. Bladder cancer risk factors. Atlanta, GA: American Cancer Society. Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-risk-factors.
9. Cartwright RA, Adib R, Glashan R, Gray BK. The epidemiology of bladder cancer in West Yorkshire. A preliminary report on non-occupational aetiologies. Carcinogenesis 1981;2:343–7.
10. Augustine A, Hebert JR, Rabat GC, Wynder EL. Bladder cancer in relation to cigarette smoking. Cancer Res 1988;48:4405–8.
11. Pitard A, Brennan P, Clavel J, Greiser E, Lopez-Abente G, Chang-Claude J, et al. Cigar, pipe, and cigarette smoking and bladder cancer risk in European men. Cancer Causes Control 2001;12:551–6.
12. Chamssuddin AK, Saadat SH, Deiri K, Zarzar MY, Abdouche N, Deeb O, et al. Evaluation of grade and stage in patients with bladder cancer among smokers and non-smokers. Arab J Urol 2013;11:165–8.
13. Crallan RA, Georgopoulos NT, Southgate J. Experimental models of human bladder carcinogenesis. Carcinogenesis 2006;27:374–81.
14. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003;3:733–44.
15. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004;83:1–1438.
16. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010;17:89–97.
17. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res 2011;71:7376–86.
18. Shapiro SG, Knapp DW, Breen M. A cultured approach to canine urothelial carcinoma: molecular characterization of five cell lines. Canine Genet Epidemiol 2015;2:15.
19. Verma N, Pink M, Rettenmeier AW, Schmitz-Spanke S. Benzo[a]pyrene-mediated toxicity in primary pig bladder epithelial cells: a proteomic approach. J Proteomics 2013;85:53–64.
20. Brockmoller J, Kaiser R, Kerb R, Cascorbi I, Jaeger V, Roots I. Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. Pharmacogenetics 1996;6:535–45.
21. Max Planck Institute for Molecular Genetics. ConsensusPathDB. Berlin, Germany: Max Planck Institute for Molecular Genetics. Available from: http://www.consensuspathdb.org/.
22. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, et al. Combination of a novel gene expression signature with a clinical nomo-gram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012;18:1323–33.
23. Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, et al. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res 2014;20:1873–83.
24. Vallot C, Stransky N, Bernard-Pierrot I, Herault A, Zucman-Rossi J, Cha-peaublanc E, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 2011;103:47–60.
25. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010;9:3.
26. Lindgren D, Sjodahl € G, Lauss M, Staaf J, Chebil G, Lovgren € K, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One 2012;7:e38863.
27. Ho T, Howard LE, Vidal AC, Gerber L, Moreira D, McKeever M, et al. Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. Clin Cancer Res 2014;20:5331–8.
28. Cancer Genome Atlas Research Network, The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011–25.
29. Putluri N, Shojaie A, Vasu VT, Nalluri S, Vareed SK, Putluri V, et al. Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One 2011;6:e21417.
30. Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol 2012;920:613–26.
31. Tanaka T, Halicka D, Traganos F, Darzynkiewicz Z. Cytometric analysis of DNA damage: phosphorylation of histone H2AX as a marker of DNA double-strand breaks (DSBs). Methods Mol Biol 2009;523:161–8.
32. Christman JK5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483–95.
33. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002;3:461–9.
34. Akopyan G, Bonavida B. Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol 2006;29:745–52.
35. Centers for Disease Control and Prevention. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. Atlanta, GA: Centers for Disease Control and Prevention; 2010.
36. Poirier MC. Chemical-induced DNA damage and human cancer risk. Discov Med 2012;14:283–8.
37. Vuillemenot BR, Hutt JA, Belinsky SA. Gene promoter hypermethylation in mouse lung tumors. Mol Cancer Res 2006;4:267–73.
38. Hutt JA, Vuillemenot BR, Barr EB, Grimes MJ, Hahn FF, Hobbs CH, et al. Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways. Carcinogenesis 2005;26:1999–2009.
39. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 2010;120:521–32.
40. Jin H, Chen JX, Wang H, Lu G, Liu A, Li G, et al. NNK-induced DNA methyltransferase1inlungtumorigenesisinA/Jmiceandinhibitoryeffects of (-)-epigallocatechin-3-gallate. Nutr Cancer 2015;67:167–76.
41. Pulling LC, Klinge DM, Belinsky SA. p16INK4a and beta-catenin alterations in rat liver tumors induced by NNK. Carcinogenesis 2001;22:461–6.
42. Pulling LC, Vuillemenot BR, Hutt JA, Devereux TR, Belinsky SA. Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. Cancer Res 2004;64:3844–8.
43. Wu CT, Wu CF, Lu CH, Lin CC, Chen WC, Lin PY, et al. Expression and function role of DNA methyltransferase 1 in human bladder cancer. Cancer 2011;117:5221–33.
44. Singh V, Sharma P, Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets 2013; 13:379–99.
45. Jung Y, Park J, Kim TY, Park JH, Jong HS, Im SA, et al. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J Mol Med 2007;85:1137–48.
46. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 2005; 280:40749–56.
47. Waterland RA. Assessing the effects of high methionine intake on DNA methylation. J Nutr 2006;136:1706S–10S.
48. Axford-Gatley RA, Wilson GJ, Feindel CM. Comparison of blood-based and asanguineous cardioplegic solutions administered at 4 degrees C. An ultrastructural morphometric study in the dog. J Thorac Cardiovasc Surg 1990;100:400–9.
49. Vu T, Jin L, Datta PK. Effect of cigarette smoking on epithelial to mesenchymal transition (EMT) in lung vancer. J Clin Med 2016;5:44.
50. Nagathihalli NS, Massion PP, Gonzalez AL, Lu P, Datta PK. Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. Mol Cancer Ther 2012;11:2362–72.